Carbidopa Anhydrous

Summary

Carbidopa Anhydrous (CHEMBL1201236) is an approved small-molecule EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor targeting DDC.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (DDC)
• Clinical trials: 91
• Chemistry: 226.23 Da · C10H14N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201236
Name	Carbidopa Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	34359
ChEBI	CHEBI:39585
Molecular formula	C10H14N2O4
Molecular weight	226.23
InChIKey	TZFNLOMSOLWIDK-JTQLQIEISA-N

SMILES: C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN

IUPAC name: (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid

ChEBI definition: 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens α- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson’s disease to reduce peripheral adverse effects of levodopa.

Pharmacological roles (ChEBI): EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, antiparkinson drug, dopaminergic agent.

Also known as: Carbidopa anhydrous, Carbidopa, l- anhydrous, SID11113507, SID26749935, SID29215028, SID50104417, SID8139862, SID93576631, SID50104418, SID144204461, CARBIDOPA

Parent form; salt/anhydrous children: CHEMBL1200748

Patent coverage: 6,426 distinct patent families (25,180 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 25,161 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
DDC	L-Aromatic amino-acid decarboxylase	Inhibition		0.1%	P20711

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Survival motor neuron protein, Fructose-bisphosphate aldolase, Prelamin-A/C, Inositol monophosphatase 1, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Thrombopoietin.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 48 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPK1	7.4	Potency	39.8	nM	CHEMBL_ACT_4533628
HSD17B10	6.8	Potency	158.5	nM	CHEMBL_ACT_4837565
SMN1	5.95	Potency	1122	nM	CHEMBL_ACT_3906492
TDP1	5.95	Potency	1122	nM	CHEMBL_ACT_3929231
KDM4E	5.65	Potency	2239	nM	CHEMBL_ACT_3721068
P0DTD1	5.45	IC50	3550	nM	CHEMBL_ACT_19964246
KDM4E	5.45	Potency	3548	nM	CHEMBL_ACT_3718896
KDM4E	5.45	Potency	3548	nM	CHEMBL_ACT_3741429
ALOX15	5.4	Potency	3981	nM	CHEMBL_ACT_4454818
ALDH1A1	5.15	Potency	7080	nM	CHEMBL_ACT_4173435
CYP1A2	5.1	AC50	7943	nM	CHEMBL_ACT_6034055

Target pathways

Aggregated over 1 target gene(s): DDC.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Catecholamine biosynthesis	1	DDC
Serotonin and melatonin biosynthesis	1	DDC

Dominant GO biological processes

GO term	Targets
kidney development	1
amino acid metabolic process	1
catecholamine metabolic process	1
response to toxic substance	1
gene expression	1
carboxylic acid metabolic process	1
dopamine biosynthetic process	1
serotonin biosynthetic process	1
biogenic amine metabolic process	1
biogenic amine biosynthetic process	1
catecholamine biosynthetic process	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 91.

Phase distribution

Phase	Trials
PHASE1	23
PHASE2	22
PHASE4	21
PHASE1/PHASE2	8
PHASE3	7
PHASE2/PHASE3	7
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06075771	PHASE4	RECRUITING	Dopaminergic Therapy for Anhedonia - 2
NCT00125567	PHASE4	COMPLETED	Stalevo in Early Wearing-Off Patients
NCT00143026	PHASE4	COMPLETED	Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson’s Disease. This Study is Not Recruiting in the United States
NCT00174239	PHASE4	TERMINATED	Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson’s Disease.
NCT00219284	PHASE4	COMPLETED	Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson’s Disease
NCT00391898	PHASE4	COMPLETED	Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson’s Disease Patients With Early Wearing-off
NCT00601978	PHASE4	WITHDRAWN	Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson’s Disease (PD) and End-of-dose Wearing Off
NCT00642356	PHASE4	TERMINATED	Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson’s Disease and Demonstrating Non-motor Symptoms of Wearing Off
NCT00888186	PHASE4	COMPLETED	Different Dyskinesias in Parkinson’s Disease and Their Relation to Levodopa Pharmacokinetics
NCT00906828	PHASE4	COMPLETED	Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors
NCT01951105	PHASE4	COMPLETED	Effect of L-dopa In Subacute Back Pain Population
NCT02346630	PHASE4	WITHDRAWN	Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation
NCT02513485	PHASE4	COMPLETED	Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa
NCT03115827	PHASE4	COMPLETED	Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
NCT04493320	PHASE4	TERMINATED	1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)
NCT04650217	PHASE4	TERMINATED	Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing
NCT04723147	PHASE4	COMPLETED	DTA (Dopaminergic Therapy for Anhedonia) Study
NCT04742348	PHASE4	WITHDRAWN	Research on Translational Outcomes of Alcohol (Project RETRO)
NCT04821830	PHASE4	COMPLETED	Vigor and the LDR in Parkinson Disease
NCT04952194	PHASE4	UNKNOWN	Clinical Study of Stalevo in the Treatment of Early Parkinson’s Disease
NCT06236230	PHASE4	UNKNOWN	Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson’s Disease
NCT03735901	PHASE3	ACTIVE_NOT_RECRUITING	Enhancement of Stroke Rehabilitation With Levodopa
NCT04520178	PHASE2/PHASE3	RECRUITING	Effects of 5HTP on the Injured Human Spinal Cord
NCT06785298	PHASE2/PHASE3	RECRUITING	Fexofenadine as Adjuvant Therapy in Parkinson Disease
NCT07151378	PHASE3	RECRUITING	Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson’s Disease
NCT07229651	PHASE2/PHASE3	RECRUITING	Metformin in Parkinson Disease
NCT07229664	PHASE2/PHASE3	RECRUITING	Vinpocetine in Patients With Parkinsonian Disease
NCT00099268	PHASE3	COMPLETED	Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson’s Disease Requiring Initiation of Levodopa Therapy
NCT00685919	PHASE2/PHASE3	COMPLETED	Peripheral Dopamine in Postural Tachycardia Syndrome
NCT01190813	PHASE3	COMPLETED	Levodopa for the Treatment of Residual Amblyopia
NCT01212484	PHASE3	COMPLETED	Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia
NCT01227655	PHASE3	COMPLETED	Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients.
NCT01429077	PHASE2/PHASE3	COMPLETED	Augmenting Language Therapy for Aphasia: Levodopa
NCT01568073	PHASE3	COMPLETED	Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson’s Disease Patients With Wearing-off Phenomenon
NCT04000919	PHASE2/PHASE3	SUSPENDED	Effects of 5HTP and LDOPA on CNS Excitability After SCI
NCT06831500	PHASE1/PHASE2	RECRUITING	Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
NCT07246278	PHASE1/PHASE2	RECRUITING	Celecoxib in Parkinson Disease as Adjuvant Therapy
NCT00200447	PHASE2	COMPLETED	An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
NCT00218023	PHASE2	COMPLETED	Medications for Stopping Cocaine Dependence and Preventing Relapse
NCT00218075	PHASE2	COMPLETED	Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).